Dr. Daniel Ngui, MD, Family Physician, talks about the pneumococcal pneumonia vaccine.

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Introduction Vaccines are biological preparations that stimulate the immune system to develop protection against specific infectious diseases.

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...

On February 21, Jared Holz, Mizuho Securities America ... maintain continued positive momentum across its PCV (pneumococcal conjugate vaccine) franchise. Apart from this franchise, its lead ...

“Early on during the pandemic, access to healthcare was limited and persons were recommended to stay home. This led to a lack of access to vaccines and a clear, early decrease i ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

For a community to be protected against contagious diseases, enough residents need to be vaccinated to provide “herd immunity.” ...

Immunoglobulin G hypogammaglobulinemia was found in 44.7% of patients with acute exacerbations of COPD receiving triple ...